Amarin Corp Plc (AMRN)

[SonamKapoor]

Thanks JL. MRC, I'm pretty sure I recall that "about" 8x from Japan linkages. So, yes, if a person wanted to discount everything out of Japan then that could certainly be a basis for their argument construction.

The decades old roots leading up to the most recent clinical trial inquiries of the past 5 years in Japan would be the Chiba Field Study -- Hisayama Study -- JELIS. As an illustration, in 1992 Japan was already looking at EPA in terms of anti-thrombotic effects and publishing their findings in Rinsho Iyaku (J Clin Ther Med); see: Goto Y and Kumagai A.

Perhaps, you think it too pat an answer my half-Asian roots as to why I would put faith in unblinded Japanese trials? Here's why. The Japanese, albeit generally speaking, are meticulous and fastidious with detail. It's not mere pedantry, although to Americans it often comes off as such. It's more for the love of the process as an end unto itself - like the Golden Ratio unfolding before their eyes. I think of them as the Germans of Asia. Or maybe it's Germans are the Japanese of Europe. Much like Germany, if I were to pull from Jungian theory, I'd say both nations display a cultural predilection toward ISTJ tendencies. How have I seen this in everyday life? Kindergartners ride the subway by themselves safely. I haven't seen any other country where people line up straight while waiting for trains on the platform - not even Germans do this. Cochrane meta-analysis don't account for these differences in our cultural maps when they strike trials from their record. So, if a Japanese patient is given a pill with instructions they will follow it faithfully for the concomitant details to be recorded by their clinician. (Now, Americans - we are a rowdy bunch, more like ESTJs).

So, yes Calder is good and his model of lipid rafts and EPA/DHA enhancing fluidity in the lipid bilayer as well as free floating outside/inside the bi-layer. These models have been extended by Olefsky in California on functioning GPR120s and dysfunctioning R270Hs effects.

Anyway, Calder was out in Seattle last year and JL & I posted here about his bio-availability research last fall (Calder works a bit with GSK (feeds into their R&D for O-3 products) and that area of the UK is a knowledge cluster for O-3s). o3 bio-avail does it matter

So, really Calder systematic reviews + trials with GSK sponsorship is a little analogous to Japanese systematic reviews + trials Amarin has sponsored. It's the pharma business, after all right? But, I like Amarin's reviews + trials on the subject of EPA. Seeing is believing and I'll do an astronomy post soon to that end. Writing about it helps me retain fluidity on my own lipid raft of understanding.